EUCTR2010-021358-20-PL进行中（未招募）不适用
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY
Pfizer Inc.235 East 42nd Street, New York, NY 100170 个研究点目标入组 230 人开始时间: 2010年11月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects =18 years. Female subjects must be of non-child bearing potential, defined as:
- •- Postmenopausal (defined as amenorrheic for at least 2 years or amenorrheic for at least 1 year together with an FSH level >40 IU/L) or
- •- Surgically sterile (defined as having had a hysterectomy and/or bilateral oophorectomy). All other female subjects (including females with tubal ligations and females that do NOT have a documented hysterectomy) will be considered to be of childbearing potential.
- •2. Clinical diagnosis of type 2 diabetes together with stages 3a, 3b or 4 CKD, based on an eGFR of 25-59 mL/min/1.73m2. 3. A history of persistent, overt albuminuria; defined as a UACR =300 mg/g
- •(=33.9 mg/mmol) or equivalent UPCR, total protein excretion or dipstick proteinuria, for greater than 3 months. A mean UACR =300 mg/g (=33.9 mg/mmol) determined from 3 consecutive morning
- •first pass urine samples AND UACR =300 mg/g (=33.9 mg/mmol) in at least 2 out of 3 of these consecutive samples during the screening period. 4. Stable background therapy of an ACE inhibitor or an ARB for at least 3 months before screening and to be maintained for the duration of the study. 5. Resting BP =150/100 mm Hg, with no history of BP >150/100 mm Hg on more than one occasion (when measured by a health care professional) in the previous 3 months.
- •6. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. 7. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. Subjects with CKD resulting from type 1 diabetes or non-diabetic CKD. 2. Subjects who are diagnosed with autosomal dominant polycystic kidney disease (ADPCKD), severe peripheral vascular disease (PVD) or obstructive uropathy. 3. Subjects who have had a kidney transplant, or who require renal replacement therapy, or are expected to require such therapy within 6 months. 4. Subjects who have a history of proteinuria >10 g/day (or equivalent UACR or UPCR) or
- •serum albumin <20 g/L (<308.6 µmol/L). 5. Subjects with poorly controlled diabetes mellitus, defined as HbA1C >9%. 6. Subjects on combination ACE inhibitor/ARB therapy. 7. Subjects on renin inhibitor therapy (aliskiren, Tekturna/Rasilez) or aliskiren-containing
- •combination therapy (Valturna). 8. Subjects on aldosterone antagonist therapy (spironolactone or eplerenone). 9. Subjects receiving or likely to receive during the study any of the following medications: Other PDE5 inhibitors must be terminated at least 14 days prior to randomization (Visit 2) and must not be taken at any time during the study; Nitrates or nitric oxide donors on either regular or intermittent basis (oral, sublingual, buccal, transdermal, inhalation or aerosols);
- •a -adrenoceptor blockers; Moderate to strong inhibitors or inducers of cytochrome P450 3A4 eg, itraconazole, erythromycin, ketoconazole, protease inhibitors. 10. Significant allergy or known intolerance to PDE5 inhibitors or any ingredient in the formulations. 11. Increased susceptibility to vasodilators including those with left ventricular outflow
- •obstruction (eg, hypertrophic obstructive cardiomyopathy). 12. History of recurrent syncope, or evidence of low BP (<90 mm Hg systolic or <40 mm Hg diastolic) or symptomatic postural hypotension. This includes relevant postural symptoms associated with a fall in systolic BP =20 mm Hg or diastolic BP =10 mm Hg on standing. 13. History of congestive heart failure (NYHA class III or IV) or unstable angina, or a history of myocardial infarction, stroke or transient ischemic attack in the previous 6 months. 14. Loss of vision in one eye due to non-arteritic ischemic optic neuropathy (NAION) regardless of whether or not this event was temporally associated with the use of a PDE5
- •inhibitor. 15. Hereditary degenerative retinal disorders (eg, retinitis pigmentosa). 16. Risk of priapism eg, sickle cell disease, multiple myeloma and myeloproliferative disorders (eg, myeloid leukemia, polycythaemia, thrombocythaemia). 17. Any relevant clinically significant abnormalities on physical examination or laboratory tests, including subjects with moderate liver function tests abnormalities >1.5 times the
- •upper limit of normal. 18. Subjects with a family history of prolonged QT syndrome, or who themselves have a QTc of >450 msec at screening, or any clinically significant ischemic changes as assessed
- •by the investigator by supine 12-lead supine ECG at screening (preference is for QT to be corrected using Fridericia’s correction).
- •19. Subjects currently experiencing any clinically significant or unstable medical condition that might limit their ability to complete the study, or to comply with the requirements of the protocol, including: dermatologic disease, hematological disease, pulmonary disease,
- •hepatic disease, gastrointestinal disease, genitourinary disease, endocrine disease, neurological disease and psychiatric disease.
- •20. Any malignancy not considered cured (except basal cell carcinoma of the skin). A subj
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of Ponsegromab in Patients with Cancer, Cachexia and Elevated GDF-15 (PROACC -1)EUCTR2022-003016-87-SKPfizer Inc.168
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of Ponsegromab in Patients withCancer, Cachexia and Elevated GDF-15.Cachexia, a loss of weight due to the catabolism of muscle and fat tissue. Theprogressive worsening of cachexia impacts a cancer patient’s quality of life and contributes to poor survival.MedDRA version: 21.1Level: LLTClassification code 10064015Term: Cancer cachexiaSystem Organ Class: 100000004861EUCTR2022-003016-87-HUPfizer Inc.168
进行中（未招募）
1 期
A clinical study to evaluate the effects and safety of three doses of Tofacitinib (a drug that is being investigated for the treatment of rheumatoid arthritis) in subjects with active Ankylosing spondylitis (AS) (a form of Arthritis)Ankylosing Spondylitis (AS)MedDRA version: 16.0Level: PTClassification code 10002556Term: Ankylosing spondylitisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-005689-39-ESPfizer Inc. 235 East 42nd Street, New York, 10017207
进行中（未招募）
1 期
A Phase 2 study of PTC857 in patients with Amyotrophic Lateral SclerosisEUCTR2021-006511-29-NOPTC Therapeutics, Inc.258
进行中（未招募）
1 期
Evaluation of EDP-938 in subjects aged 28 days to 24 months infected with respiratory syncytial virus (RSV)Respiratory Syncytial Virus (RSV)MedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-001966-13-ESEnanta Pharmaceuticals, Inc.90